MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML

Abstract Background Oral azacitidine improves survival in patients with AML in first complete remission who are not candidates for allogeneic transplantation. Most favorable-risk AML patients harbor molecular markers enabling sensitive measurable residual disease (MRD) monitoring. While MRD is a wel...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Noa Hurvitz, Irina Amitai, Ilana Levy Yurkovski, Ariella Tvito, Yishai Ofran, Tzvika Porges, Ofir Wolach, Adi Sherban, Noa Gross Even-Zohar, Vladimir Vainstein, Arnon Haran, Shlomzion Aumann, Robert Mikhelashvili, Avraham Frisch, Boaz Nachmias
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Springer 2026-05-01
Serie:	Annals of Hematology
Ämnen:	Acute myeloid leukemia Maintenance Oral azacitidine Measurable residual disease Onureg
Länkar:	https://doi.org/10.1007/s00277-026-07054-5
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!